English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

An estimated 5.7 million adults with heart failure (HF) currently burden the human, medical, and financial resources of the United States. By 2030, this number is expected to increase to more than 8 million. In 2012, the total cost of HF in the United States was estimated at $30.7 billion, which is expected to increase to $69.7 billion by 2030. HF contributes substantially to mortality and is documented on 1 in 9 death certificates in the United States (1). HF mortality 1 y after diagnosis appears to be declining in the 21st century according to Medicare data: 31.7% in 1999 to 29.6% in 2008 (2). These improvements have been attributed to evidence-based approaches in the management of HF, including guideline-directed medical therapy, coronary revascularization, implantable cardioverter defibrillators, and cardiac resynchronization therapy (CRT) in which both the right and the left ventricles are paced synchronously to augment cardiac output (1).

the journal of nuclear medicine

Quantitative Radionuclide Assessment of Cardiac Dyssynchrony: Breakthrough in Patient Selection for Cardiac Resynchronization Therapy for Refractory Heart Failure?